Monsenso signed a new agreement with a leading pharmaceutical company to implement its solution for decentralised patient-centric real-world data collection in a chronic disease area. Under the new agreement, Monsenso will deliver and support real-world patient data collection for a decentralised patient-centric study expected to take place over the next 12 months. The agreement and the solution delivered build on Monsenso's existing platform, which will be customised to support the specific study and the disease of the patient group.

It also includes developing new features to support the patient-centric real- world data study, which will position Monsenso's solution even stronger in the future. The project comes one year into the start of the PhaseV research project, where Monsenso further develops its solution to fully support decentralised real-world data studies and trials in collaboration with leading pharmaceutical companies and research institutions. The agreement is not expected to impact Monsenso's revenue projections for 2023, but it is expected to contribute to the growth in the coming years.